Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 5, pp 1095–1100 | Cite as

Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation

  • Martin ŠímaEmail author
  • Martin Vodička
  • Věra Marešová
  • Tomáš Šálek
  • Radomír Čabala
  • Ondřej Slanař
Research Article

Abstract

Background Although measurement of drug serum levels is an objective direct method for testing compliance, it can be distorted by “white-coat compliance” or by variations in drug elimination. Objective The aim of this prospective study was to evaluate the prevalence of noncompliance with perindopril therapy in adult out-patients using pharmacokinetic simulations. The additional aim was to compare the predictive performance of two glomerular filtration rate markers—creatinine and cystatin C. Setting Department of Cardiology, Tomas Bata Regional Hospital in Zlín, Czech Republic. Method Perindoprilat pharmacokinetic models individualized according to patient characteristics were compared with measured perindoprilat serum concentrations to document compliance. Linear regression was used to evaluate the relations between perindoprilat clearance and glomerular filtration rate estimated using creatinine and cystatin C. Main outcome measure Assessment of non-compliance with medication using drug concentration measurements reinforced with therapeutic drug monitoring. Results Non-detectable perindoprilat levels were observed in 26.1% of patients. Another 21.7% were classified as non-compliant based on therapeutic drug monitoring pharmacokinetic simulations. Volume of distribution, clearance and half-life median value (interquarti°range) for perindoprilat were 408.3 (360.4–456.8) L, 10.1 (4.9–17.0) L h−1 and 24.7 (19.4–62.7) h, respectively. Linear regression models showed tight relationship between cystatin C and perindoprilat clearance. Conclusions Assessment of adherence with medication reinforced with therapeutic drug monitoring and pharmacokinetic simulations is proposed as an optimal method reducing disadvantages of simple drug concentration measurements. Cystatin C proves to be better surrogate marker for perindoprilat elimination than creatinine.

Keywords

ACE inhibitors Compliance Creatinine Cystatin C Perindopril Therapeutic drug monitoring 

Notes

Acknowledgements

We thank Dr. Natasa Lekic for English language editing.

Funding

This work was supported by the Charles University Project Progres Q25 and a grant No. SVV 260373.

Conflicts of interest

The authors declare that there are no conflicts of interest regarding of this paper.

References

  1. 1.
    Sindone A, Erlich J, Lee C, Newman H, Suranyi M, Roger SD. Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to? Intern Med J. 2016;46:364–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e5641.CrossRefGoogle Scholar
  3. 3.
    Borghi C, Tartagni E. The older patient with hypertension: care and cure. Ther Adv Chronic Dis. 2012;3:231–6.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.CrossRefPubMedGoogle Scholar
  5. 5.
    Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 1998;46:95–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18:2024–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34:87–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Strauch B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, Chytil L, Marešová V, Kurcová I, Holaj R, Wichterle D, Widimský J. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Verpooten GA, Genissel PM, Thomas JR, De Broe ME. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Br J Clin Pharmacol. 1991;32:187–92.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Meeusen JW, Rule AD, Voskoboev N, Baumann NA, Lieske JC. Performance of cystatin C- and creatinine-based estimated glomerular filtration rate equations depends on patient characteristics. Clin Chem. 2015;61:1265–72.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699–707.PubMedGoogle Scholar
  13. 13.
    Brou NA, Jacqz-Aigrain E, Zhao W. Cystatin C as a potential biomarker for dosing of renally excreted drugs. Br J Clin Pharmacol. 2015;80:20–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Pharmacology, First Faculty of MedicineCharles University and General University Hospital in PraguePragueCzech Republic
  2. 2.Department of PharmacyTomas Bata Regional HospitalZlínCzech Republic
  3. 3.Institute of Forensic Medicine and Toxicology, First Faculty of MedicineCharles University and General University Hospital in PraguePragueCzech Republic
  4. 4.Department of Clinical Biochemistry and PharmacologyTomas Bata Regional HospitalZlínCzech Republic

Personalised recommendations